Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001859-43
    Sponsor's Protocol Code Number:CA209-743
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-06-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-001859-43
    A.3Full title of the trial
    A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First
    Line Therapy in unresectable Pleural Mesothelioma
    Studio di Fase III, randomizzato, in aperto, di nivolumab in combinazione con ipilimumab rispetto a pemetrexed con cisplatino o carboplatino come terapia di prima linea nel mesotelioma pleurico non resecabile
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Randomized Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients.
    Studio randomizzato di nivolumab in combinazione con ipilimumab rispetto a pemetrexed con cisplatino o carboplatino come terapia di prima linea in pazienti con mesotelioma pleurico non resecabile
    A.3.2Name or abbreviated title of the trial where available
    -
    CA209-743
    A.4.1Sponsor's protocol code numberCA209-743
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1182-2322
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBristol-Myers Squibb International Corporation
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBristol-Myers Squibb International Corporation
    B.5.2Functional name of contact pointGlobal Submission Management-Clinic
    B.5.3 Address:
    B.5.3.1Street AddressParc de l'Alliance - Avenue de Finlande, 4
    B.5.3.2Town/ cityBraine-l'Alleud
    B.5.3.3Post code1420
    B.5.3.4CountryBelgium
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailmg-gsm-ct@bms.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNivolumab - 10ml vial - CLINICAL
    D.3.2Product code [BMS-936558]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNIVOLUMAB
    D.3.9.1CAS number 946414-94-4
    D.3.9.2Current sponsor codeBMS-936558-01
    D.3.9.4EV Substance CodeSUB32944
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIpilimumab
    D.3.2Product code [BMS-734016]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNipilimumab
    D.3.9.1CAS number 477202-00-9
    D.3.9.2Current sponsor codeBMS-734016
    D.3.9.4EV Substance CodeSUB22577
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name PARAPLATIN - 450 MG/45 ML SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO
    D.2.1.1.2Name of the Marketing Authorisation holderBRISTOL MYERS SQUIBB S.R.L.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code NA
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCARBOPLATINO
    D.3.9.1CAS number 41575-94-4
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance CodeSUB06614MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cisplatin Neocorp 1 mg/ml (100 mg/ vials)
    D.2.1.1.2Name of the Marketing Authorisation holderNeocorp GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code NA
    D.3.4Pharmaceutical form Concentrate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCISPLATINO
    D.3.9.1CAS number 15663-27-1
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance CodeSUB07483MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Alimta
    D.2.1.1.2Name of the Marketing Authorisation holderEli Lilly Nederland B.V.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code NA
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPEMETREXED DISODICO
    D.3.9.1CAS number 150399-23-8
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance CodeSUB03669MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cisplatin-Ebewe
    D.2.1.1.2Name of the Marketing Authorisation holderEBEWE Pharma
    D.2.1.2Country which granted the Marketing AuthorisationPoland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code NA
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCISPLATINO
    D.3.9.1CAS number 15663-27-1
    D.3.9.2Current sponsor code000
    D.3.9.3Other descriptive nameCISPLATIN
    D.3.9.4EV Substance CodeSUB07483MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cisplatin TEVA
    D.2.1.1.2Name of the Marketing Authorisation holderTEVA GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNA
    D.3.2Product code NA
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCISPLATINO
    D.3.9.1CAS number 15663-27-1
    D.3.9.2Current sponsor code000
    D.3.9.3Other descriptive nameCISPLATIN
    D.3.9.4EV Substance CodeSUB07483MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Opdivo (100 mg/10 ml)
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb Pharma EEIG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameNIVOLUMAB - 10ml vial-COMMERCIAL
    D.3.2Product code [BMS-936558]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnivolumab
    D.3.9.1CAS number 946414-94-4
    D.3.9.2Current sponsor codeBMS-936558-01
    D.3.9.3Other descriptive nameBMS936558
    D.3.9.4EV Substance CodeSUB32944
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Untreated unresectable Pleural Mesothelioma
    Mesotelioma pleurico non resecabile non precedentemente trattato
    E.1.1.1Medical condition in easily understood language
    Cancer of mesothelial tissue in the lungs
    Carcinoma del tessuto mesoteliale nei polmoni
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10059518
    E.1.2Term Pleural mesothelioma malignant
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare overall survival (OS) of nivolumab combined with
    ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first
    line treatment in patients with unresectable malignant pleural
    mesothelioma.
    Confrontare la sopravvivenza globale (overall survival, OS) di nivolumab in combinazione con ipilimumab rispetto a pemetrexed più un regime con cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    E.2.2Secondary objectives of the trial
    - To assess the objective response rate (ORR) as determined by blinded
    independent central review (BICR), of nivolumab combined with
    ipilimumab and pemetrexed plus cisplatin or carboplatin as first line
    treatment in patients with unresectable malignant pleural mesothelioma.
    - To assess the Disease Control Rate (DCR) as determined by BICR, of
    nivolumab combined with ipilimumab and pemetrexed plus cisplatin or
    carboplatin as first line treatment in patients with unresectable
    malignant pleural mesothelioma.
    - To assess progression free survival (PFS) as determined by BICR, of
    nivolumab combined with ipilimumab and pemetrexed plus cisplatin or
    carboplatin as first line treatment in patients with unresectable
    malignant pleural mesothelioma.
    - To evaluate whether PD-L1 expression is a predictive biomarker for
    ORR, PFS, and OS.
    • Valutare il tasso di risposta obiettiva (objective response rate, ORR), determinato dal Comitato di revisione indipendente in cieco (Blinded Independent Committee Review, BICR), di nivolumab in combinazione con ipilimumab e pemetrexed più cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    • Valutare il tasso di controllo della malattia (Disease Control Rate, DCR), determinato dal BICR, di nivolumab in combinazione con ipilimumab e pemetrexed più cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    • Valutare la sopravvivenza libera da progressione (PFS), determinata dal Comitato di revisione indipendente in cieco, di nivolumab in combinazione con ipilimumab e pemetrexed più cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    • Valutare se l’espressione di PD-L1 sia un biomarcatore predittivo per ORR, PFS e OS.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives

    Pharmacogenetics
    Version: Version 01
    Date: 25/05/2016
    Title: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First
    Line Therapy in unresectable Pleural Mesothelioma (Section 5.6.4 Additional Research)
    Objectives: This collection for additional research is intended to expand the translational R&D capability at Bristol-Myers Squibb, and will support as yet undefined research aims that will advance our understanding of disease and options for treatment. It may also be used to support health authority requests for analysis, and advancement of pharmacodiagnostic development to better target drugs to the right subjects. This may also
    include genetic/genomic exploration aimed at exploring disease pathways, progression and response to treatment etc.

    Pharmacogenomics
    Version: Version 01
    Date: 25/05/2016
    Title: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma (Section 5.6.4 Additional Research)
    Objectives: This collection for additional research is intended to expand the translational R&D capability at Bristol-Myers Squibb, and will support as yet undefined research aims that will advance our understanding of disease and options for treatment. It may also be used to support health authority requests for analysis, and advancement of pharmacodiagnostic development to better target drugs to the right subjects. This may also include genetic/genomic exploration aimed at exploring disease pathways, progression and response to treatment etc.

    Farmacogenetica
    Versione: Version 01
    Data: 25/05/2016
    Titolo: Studio di Fase III, randomizzato, in aperto, di nivolumab in combinazione con ipilimumab rispetto a pemetrexed con cisplatino o carboplatino come terapia di prima linea nel mesotelioma pleurico non resecabile (Sezione 5.6.4 Additional Research)
    Obiettivi: Questa raccolta di campioni per la ricerca addizionale ha lo scopo di ampliare la capacità traslazionale della ricerca e sviluppo di Bristol-Myers Squibb e sosterrà gli obiettivi di ricerca ancora non definiti che porteranno avanti la nostra comprensione della malattia e le opzioni per il trattamento. Potrebbe anche essere utilizzata per supportare le richieste di analisi da parte dell’autorità competente, nonché l'avanzamento dello sviluppo farmacodiagnostico al fine di migliorare la destinazione dei farmaci ai soggetti giusti. Questo può anche includere esplorazione genetica / genomica tesa ad esplorare i percorsi di malattia, la progressione e la risposta al trattamento, ecc

    Farmacogenomica
    Versione: Version 01
    Data: 25/05/2016
    Titolo: Studio di Fase III, randomizzato, in aperto, di nivolumab in combinazione con ipilimumab rispetto a pemetrexed con cisplatino o carboplatino come terapia di prima linea nel mesotelioma pleurico non resecabile (Sezione 5.6.4 Additional Research)
    Obiettivi: Questa raccolta di campioni per la ricerca addizionale ha lo scopo di ampliare la capacità traslazionale della ricerca e sviluppo di Bristol-Myers Squibb e sosterrà gli obiettivi di ricerca ancora non definiti che porteranno avanti la nostra comprensione della malattia e le opzioni per il trattamento. Potrebbe anche essere utilizzata per supportare le richieste di analisi da parte dell’autorità competente, nonché l'avanzamento dello sviluppo farmacodiagnostico al fine di migliorare la destinazione dei farmaci ai soggetti giusti. Questo può anche includere esplorazione genetica / genomica tesa ad esplorare i percorsi di malattia, la progressione e la risposta al trattamento, ecc
    E.3Principal inclusion criteria
    -) Male and female subjects (over 18 years of age)
    -) Histologically proven diagnosis of MPM, thoracoscopy is highly
    recommended.
    -) Advanced unresectable disease that is not amenable to therapy with
    curative intent (surgery with or without chemotherapy). Subjects that
    refuse potentially curative surgery are ineligible
    -) Available (archival and/or fresh) pathological samples for centralized
    PD-L1 IHC testing during the screening period. Subjects cannot be
    randomized until the tumor tissue for PD-L1 testing has been received at
    the Central Lab, however, the result of the testing is not required prior to
    randomization. Subjects can initiate therapy before the result of PD-L1
    testing is available.
    -) Prior palliative radiotherapy is acceptable, but at least 14 days must
    have passed since the administration of the radiotherapy and all signs of
    toxicity must have remitted.
    - ECOG Performance Status of 0-1.
    -) Measurable disease, defined as at least 1 lesion measured in up to two
    positions at three separate levels on transverse cuts of CT scan that is
    suitable for repeated assessment using adapted modified Response
    Evaluation Criteria in Solid Tumors [m-RECIST] for pleural mesothelioma
    -) Adequate hematological, renal and hepatic functions.
    linguaggio semplificato e leggermente modificato in accordo al protocollo emendato rev01:
    Uomini e donne (di età superiore ai 18 anni)
    Diagnosi istologicamente comprovata di MPM, toracoscopia altamente raccomandata.
    Evidenza di malattia avanzata non resecabile non suscettibile di terapia con intento curativo (intervento chirurgico con o senza chemioterapia). Non sono idonei i soggetti che rifiutano l’intervento chirurgico potenzialmente curativo per malattia ricorrente.
    Disponibilità di campioni patologici (di archivio e/o freschi) per l’analisi IHC centralizzata di PD-L1 durante il periodo di screening. I soggetti non potranno essere randomizzati fino alla ricezione del tessuto tumorale per il test del PD-L1 da parte del laboratorio centrale, ma il risultato dell’analisi tuttavia non è richiesto prima della randomizzazione. I pazienti possono iniziare la terapia prima che il risultato del test PD-L1 sia disponibile.
    Una precedente radioterapia palliativa è accettabile, ma devono essere trascorsi almeno 14 giorni dalla somministrazione della radioterapia e tutti i segni di tossicità devono essere rientrati.
    Performance status ECOG 0-1
    Malattia misurabile definita come almeno una lesione misurata fino a due posizioni su tre livelli separati di sezioni trasversali della TAC che sia idonea per valutazioni ripetute utilizzando i criteri RECIST modificati (m-RECIST) per il mesotelioma pleurico.
    Funzionalità ematologica, renale ed epatica idonee
    E.4Principal exclusion criteria
    -) Primitive peritoneal, pericardial and tunica vaginalis testis
    mesotheliomas
    -) Brain metastasis, except if surgically resected or treated with
    stereotaxic radiotherapy with no evolution within
    the 3 months before inclusion, and asymptomatic. In addition, subjects
    must be either off corticosteroids, or on a
    stable or decreasing dose of less or equal to 10 mg daily prednisone (or
    equivalent) for at least 2 weeks prior to randomization,
    -) Prior treatment with adjuvant or neoadjuvant chemotherapy; radical
    pleuropneumonectomy with or without
    intensity modulated radiotherapy, or non-palliative RT
    -) Prior intraoperative or intracavitary chemotherapy for pleural
    mesothelioma
    -) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4
    antibody, or any other antibody or drug specifically targeting T-cell costimulation
    or checkpoint pathways.
    -) History of chronic inflammatory or autoimmune disease
    -) Concurrent or prior malignancy requiring or anticipated to require
    concurrent intervention
    -) Subjects with interstitial lung disease that is symptomatic or may
    interfere with the detection or management of
    suspected drug-related pulmonary toxicity.
    linguaggio semplificato e leggermente modificato in accordo al protocollo emendato rev01:
    Mesoteliomi primitivi del peritoneo, del pericardio e della tunica vaginale o del testicolo.
    Metastasi cerebrali, tranne se resecate chirurgicamente o trattate con radioterapia stereotassica senza evoluzione nei 3 mesi precedenti l’inclusione e asintomatiche. Inoltre, i soggetti non devono assumere corticosteroidi o essere a dose stabile o in diminuzione di < = 10 mg di prednisone (o equivalente) al giorno da almeno 2 settimane prima della randomizzazione.
    Precedente terapia con chemioterapia adiuvante, neoadiuvante, pleuropneumonectomia radicale con o senza radioterapia ad intensità modulata ed RT non palliativa
    Precedente chemioterapia endocavitaria o intraoperatoria per il mesotelioma pleurico
    Precedente trattamento con un anticorpo anti-PD1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 o cn qualsiasi altro anticorpo o farmaco specificamente mirato alla co-stimolazione delle cellule T o le vie di checkpoint.
    storia di malattia cronica infiammatoria o autoimmune
    Altra neoplasia maligna attiva che richiede intervento concomitante o dove l’intervento concomitante è anticipato durante lo studio.
    Soggetti con malattia polmonare interstiziale sintomatica o che potrebbe interferire con la rilevazione o la gestione di sospette tossicità polmonari correlate al farmaco.
    E.5 End points
    E.5.1Primary end point(s)
    To compare overall survival (OS) of nivolumab combined with
    ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first
    line treatment in patients with unresectable malignant pleural
    mesothelioma.
    Confrontare la sopravvivenza globale (overall survival, OS) di nivolumab in combinazione con ipilimumab rispetto a pemetrexed più un regime con cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The study will end when analysis of overall survival is complete. Every
    effort will be made to collect survival data on all subjects including
    subjects withdrawn from treatment for any reason, who are eligible to
    participate in the study and who have not withdrawn consent for
    survival data collection. If the death of a subject is not reported, all dates in this study representing a date of subject contact will be used in
    determination of the subject's last known date alive.
    Lo studio si concluderà quando l’analisi della sopravvivenza globale è completa. Ogni tentativo sarà fatto per raccogliere i dati della sopravvivenza in tutti i soggetti inclusi quelli che hanno ritirato il consenso al trattamento per qualsiasi ragione, che sono elegibili a partecipare allo studio e che non hanno ritirato il consenso per la raccolta dei dati di sopravvivenza. Se la morte di un paziente non è riportata, tutte le date in questo studio rappresentanti una data di contatto del paziente saranno usate per determinare l’ultima data conosciuta in cui il paziente era in vita.
    E.5.2Secondary end point(s)
    - To assess the objective response rate (ORR) as determined by blinded
    independent central review (BICR), of nivolumab combined with
    ipilimumab and pemetrexed plus cisplatin or carboplatin as first line
    treatment in patients with unresectable malignant pleural mesothelioma.
    - To assess the Disease Control Rate (DCR) as determined by BICR, of
    nivolumab combined with ipilimumab and pemetrexed plus cisplatin or
    carboplatin as first line treatment in patients with unresectable
    malignant pleural mesothelioma.
    - To assess progression free survival (PFS) as determined by BICR, of
    nivolumab combined with ipilimumab and pemetrexed plus cisplatin or
    carboplatin as first line treatment in patients with unresectable
    malignant pleural mesothelioma.
    - To evaluate whether PD-L1 expression is a predictive biomarker for
    ORR, PFS, and OS.
    • Valutare il tasso di risposta obiettiva (objective response rate, ORR), determinato dal Comitato di revisione indipendente in cieco (Blinded Independent Committee Review, BICR), di nivolumab in combinazione con ipilimumab e pemetrexed più cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile
    • Valutare il tasso di controllo della malattia (Disease Control Rate, DCR), determinato dal BICR, di nivolumab in combinazione con ipilimumab e pemetrexed più cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    • Valutare la sopravvivenza libera da progressione (PFS), determinata dal Comitato di revisione indipendente in cieco, dinivolumab in combinazione con ipilimumab e pemetrexed più cisplatino o carboplatino come trattamento di prima linea in pazienti con mesotelioma pleurico non resecabile.
    • Valutare se l’espressione di PD-L1 sia un biomarcatore predittivo per ORR, PFS e OS.
    E.5.2.1Timepoint(s) of evaluation of this end point
    For the definitions of ORR, DCR, and PFS;
    All randomized subjects will be monitored by radiographic assessment
    on an every-6-week schedule (plus minus 7 days) for the first 12 months
    (until week 48) and every 12 weeks (plus minus 7 days) thereafter
    [beginning from the first on-study assessment on week 6 (plus minus7
    days)], to determine changes in tumor size.
    Per la determinazione di ORR, DCR, e PFS;
    Tutti i soggetti randomizzati saranno monitorati con valutazioni radiologiche ogni 6 settimane (più o meno 7 giorni) per i primi 12 mesi (fino alla settimana 48) e poi ogni 12 settimane (più o meno 7 giorni) [iniziando con la prima valutazione di studio, alla settimana 6 /più o meno 7 giorni)], per determinare le variazioni nelle dimensioni del tumore.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA49
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Chile
    Colombia
    Japan
    Mexico
    Russian Federation
    South Africa
    Turkey
    United States
    Belgium
    France
    Germany
    Greece
    Italy
    Netherlands
    Poland
    Romania
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last follow up visit of the last patient
    Ultima visita di follow-up dell’ultimo soggetto
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days8
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days18
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 144
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 176
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Subjects unable to give their written consent may only be enrolled in the study with the consent of a legally acceptable representative (Revprot02 Section 2.3)
    I soggetti incapaci di prestare il loro consenso possono essere arruolati nello studio solo con il consenso di un rappresentante legale accettabile (Revprot02 Sezione 2.3)
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state56
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 320
    F.4.2.2In the whole clinical trial 800
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the conclusion of the study, subjects who continue to demonstrate clinical benefit will be eligible to receive BMS supplied study drug.
    Study drug will be provided via an extension of the study, a rollover study requiring approval by responsible health authority and ethics committee or through another mechanism at the discretion of BMS.
    Al termine dello studio, i soggetti che continuano a dimostrare beneficio clinico saranno elegibili a ricevere il farmaco in studio fornito da BMS. Il farmaco in studio verrà fornito tramite un'estensione dello studio, un rollover dello studio che richiede l'approvazione da parte dell’ autorità sanitaria responsabile e dei comitati etici o attraverso un altro meccanismo a discrezione di BMS.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-12-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-12-16
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-04-24
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:18:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA